PDL BioPharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales
PDL BioPharma, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales of $0 for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales · last filed 2019-11-06
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for the quarter ending 2019-03-31 was $0.00.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for the quarter ending 2018-09-30 was $3.12M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 9 month |
|---|---|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | ||
| 2018-09-30 | $3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $1.56M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$1.56M 10-Q · filed 2018-08-09 |